Table 4.
Characteristics of patients failing treatment-free remission.
| Parameter | Overall | Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|---|---|
| TFR failure, n∗ (%) | 3∗ (25) | — | — | — | |
| Follow-up after TKI discontinuation in months, median [range] | 13 [9–14] | 9 | 13 | 14 | |
| Time to molecular relapse in months, median [range] | 3 [3–4] | 3 | 4 | 3 | |
| Time to recommencement of TKI therapy in months, median [range] | 2 [1–2] | 1 | 2 | 2 | |
| Time to MMR after molecular relapse in months, median [range] | 1 [1–3] | 1 | 1 | 3 | |
| Time to DMR after failed TFR in months, median [range] | 4 [2–6] | 2 | 4 | 6 | |
|
| |||||
| Response at last follow-up, n (%) | MR4.0 | 1 (33) | X | ||
| MR4.5 | 2 (67) | X | X | ||
TKI: tyrosine kinase inhibitor; DMR: deep molecular response; MR4.5: ≥4.5-log reduction in BCR-ABL1 transcripts from baseline; MR4.0: ≥4.0-log reduction in BCR-ABL1 transcripts from baseline; MMR: major molecular response. ∗Total TFR cohort = 12 patients.